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Abstract
Objective. Under the auspices of the European League Against Rheumatism (EULAR), a study group of
investigators representing European biologic DMARD (bDMARD) registers was convened. The purpose of
this initial assessment was to collect and compare a cross section of patient characteristics and collate
information on the availability of potential confounders within these registers.
Methods. Baseline characteristics of patients starting their first bDMARD in an arbitrary year (2008) for the
treatment of RA, including demographic and disease characteristics, bDMARD drug details and co-mor-
bidities, were collected and compared across 14 European bDMARD registers.
Results. A total of 5320 patients were included. Half the registers had restricted recruitment to certain
bDMARDs during the study year. All registers‘ collected data on age, gender, disease duration, seroposi-
tivity for IgM-RF and 28-joint DAS (DAS28). The mean DAS28 ranged from 4.2 to 6.6 and the mean HAQ
from 0.8 to 1.9. Current smoking ranged from 9% to 34%. Nine registers reported co-morbidities with
varying prevalence.
Conclusion. In addition to demonstrating European-wide collaboration across rheumatology bDMARD
registers, this assessment identified differences in prescribing patterns, recruitment strategies and data
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items collected. These differences need to be considered when applying strategies for combined analysis.
The lack of a common data model across Europe calls for further work to harmonize data collection
across registers.
Key words: rheumatoid arthritis, epidemiology, biologic therapies, outcome measures, study design.
Rheumatology key messages
. European RA biologic registers vary in design, recruitment and data items collected.
. Patient characteristics at the start of biologic therapies vary across European RA biologic registers.
. Patient and register differences are important when combining RA registers to study rare outcomes.
Introduction
While biologic DMARDs (bDMARDs) have significantly im-
proved outcomes for patients with RA, rare adverse
events remain a concern. Many European countries
have set up national bDMARD registers to evaluate
long-term outcomes. However, despite large patient num-
bers in these registers, it is likely that individually they lack
power to confidently rule out moderate yet clinically
meaningful increases in risks of rare potential adverse
events, such as lymphoma [16]. Under the auspices of
the European League Against Rheumatism (EULAR), a
study group of investigators representing European
bDMARD registers was convened to explore the feasibility
of combined analyses.
A challenge when combining large datasets is under-
standing the extent of heterogeneity, particularly as
marked differences in important confounders may mask
potential exposure effects on outcome. Across Europe
there are significant differences in the use of bDMARDs
for RA related to acceptability, availability and affordability
[7, 8]. These may result in variations in patient disease
activity, duration or severity at the start of bDMARD ther-
apy, which could lead to differences in the expected rates
of adverse events. This is particularly important since cer-
tain adverse events, such as lymphoma, have been linked
to disease activity; others, such as serious infection risk,
are also linked to a number of co-morbidities [912].
Modern statistical techniques can allow for such variation
and control for these potential confounders, but more dif-
ferences may exist across countries regarding other un-
measured confounders. Therefore, information on these
variables for statistical adjustment is important.
With these challenges in mind, the purpose of this initial
assessment was to (i) identify and create a collaborative
group of European bDMARD registers, (ii) collect and
compare information on characteristics of patients
across these registers and (iii) collate information on the
availability of important potential confounders within these
registers.
Methods
Eighteen European national registers were invited to par-
ticipate in this analysis to provide cross-sectional informa-
tion on all registered patients starting their first bDMARD
between 1 January 2008 and 31 December 2008 for the
treatment of RA. Summative baseline data were collected
from each register, including patient demographics (age,
gender, smoking status), disease characteristics (disease
duration, seropositivity for IgM-RF, disease activity meas-
ures), current anti-rheumatic treatment [patients starting
each bDMARD, patients on concomitant MTX and mean
dosage, patients on oral prednisolone and mean dosage,
patients on other non-biologic DMARDs (nbDMARDs) and
number of previous nbDMARDs] and important co-mor-
bidities (hypertension, cardiovascular disease, diabetes,
chronic obstructive lung disease, depression, previous
cancer, previous tuberculosis).
Each register entered values into a template Excel
(2007; Microsoft, Redmond, WA, USA) spreadsheet,
including the amount of missing data for each variable.
The data were then emailed to the analysis coordinator
in the UK and collated for comparison. All registers were
approved and all patients consented according to the
local ethical approval for each register. No additional eth-
ics approval was required to undertake the current study.
Results
Characteristics of the participating registers
Fourteen European bDMARD registers agreed to take part
in this initial exercise. All registers recruited adult patients
with a diagnosis of RA starting a biologic and no registers
had any exclusion criteria, with the exception of some
registers limiting recruitment to certain biologic drugs
only (supplementary Table S1, available at Rheumatology
Online). A total of 5320 patients with RA initiating their first
ever bDMARD were included (Table 1).
All registers collected data on age, gender, disease dur-
ation, seropositivity for IgM-RF and 28-joint DAS (DAS28)
(Table 2). The majority also collected data on the individ-
ual components of the DAS28: swollen joint count, tender
joint count, CRP, ESR and patient global assessment.
Baseline MTX use was captured in all 14 registers. Oral
prednisolone use was captured in 13 registers. Doses of
MTX and prednisolone were captured in seven and eight
registers, respectively. All registers but one collected co-
morbidity data. Four registers collected co-morbidity data
but were unable to provide the details for this analysis;
reasons for this included a large proportion of missing
data in one register. In the other three registers, these
www.rheumatology.oxfordjournals.org 1075
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data are not contained within the registers but are avail-
able through national record linkage, which could not be
performed for the purpose of this analysis.
Characteristics of bDMARD initiators
Mean age at the start of the first bDMARD was in the mid-
50s in all studies, with proportionally more female partici-
pants (Table 2). Average disease duration ranged from 8
years in the Netherlands, Spain and Switzerland to 13
years in Finland. The percentage of IgM-RF-seropositive
patients ranged from 59% in the UK to 92% in Hungary.
Current smokers ranged from 9% in Portugal to 34% in
Switzerland. The proportion of patients ever to have
smoked ranged from 23% in Portugal to 60% in the UK
and 61% in Italy. Disease activity varied across the regis-
ters: mean DAS28 ranged from 4.2 in Switzerland to 6.6 in
Slovenia and mean HAQ ranged from 0.8 in Norway (mod-
ified HAQ) and 0.9 in Switzerland to 1.9 in the UK.
Concomitant MTX use at baseline ranged from 41% in
Switzerland to 91% in Slovenia. The use of other non-MTX
nbDMARDs ranged from 8% in Norway to 65% in Finland.
The mean number of previous DMARDs (reported in nine
registers) ranged from two in Italy and Norway to four
in Slovenia. There was also variability in the frequency
of co-morbidities (Table 2). The proportion of patients
with hypertension ranged from 8% of patients in
Switzerland to 39% of patients in Germany. Depression
ranged from 1% in Norway to 18% in Sweden and 20% in
the UK.
Discussion
This first collaboration of the EULAR Study Group for
Registers and Observational Drug Studies has been a
success with respect to participation; 14 registers
provided detailed summative statistics on patients com-
mencing their first bDMARD during a single calendar year.
A single calendar year was chosen in order to limit patient
variability in relation to calendar year, as it is known that
patients who have started bDMARD therapies over the
years have also changed even within a single country
[13, 14]. The chosen date was arbitrary but did reflect
the midway point between the start of many registers
and the date of the current analysis. It is likely that the
mean value of many of the data elements would have
differed if an alternative year had been chosen, but the
main finding of differences between registers and patients
would likely still have emerged.
The different bDMARDs recruited to each register may
represent the differential use of these agents in some
countries, but it also highlights the different study designs
of the registers. For example, the UK register was de-
signed as a prospective cohort study with planned
sample size recruitment; only certain cohorts were open
in 2008. This is compared with Denmark, Sweden and
Switzerland, where recruitment is built into the routine
care of patients, or Spain, where all patients at participat-
ing centres prescribed bDMARDs are included. Ultimately
this may introduce an element of selection bias into cer-
tain registers and therefore we cannot comment on the fullT
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degree of overlap (or not) between registers. Furthermore,
total recruitment figures and proportions by drug cannot
be interpreted as representative of the comparative use of
such drugs across Europe.
Despite differences in registration criteria, all patients
included were starting their first bDMARD following failure
of nbDMARDs and thus should be at a comparable point
in disease progression. Therefore most differences should
not be explained solely by the choice of drugs under re-
cruitment. Instead, prescribing guidelines, local practice
and cultural differences may influence differences across
Europe [7, 8]. In this study, DAS28 values were lowest in
Finland, Norway and Switzerland and highest in the Czech
Republic, Slovenia and the UK. It has been previously
noted that the UK has strict guidelines on bDMARDs, lim-
ited to those with persistently high disease activity (DAS28
>5.1) despite two nbDMARDs. In contrast, Denmark and
Norway are recognized as having more liberal guidelines.
An early analysis found that up to 50% of patients starting
a bDMARD in the years 20013 would not have been eli-
gible for this treatment had they been resident in the UK
[1517]. Compared with the UK, Slovenia has a lower
DAS28 threshold of 4.2 for commencing the first
bDMARD. However, it also specifies at least eight joints
to be affected, which may explain the high DAS28 in these
patients [18].
One of the most important predictors of future adverse
events may be patient co-morbidities at the start of treat-
ment. There were differences in co-morbidities recorded
across studies, including which co-morbidities were re-
corded and how. For example, Sweden defined depres-
sion using linked patient records of hospitalizations,
primary care outpatient visits and prescriptions and there-
fore may also include patients prescribed tricyclic anti-
depressants for chronic pain. In comparison, the UK
physician is asked to record whether a patient has ever
had depression. These discrepancies highlight that while
there may be true differences in the rates of certain co-
morbidities across populations, it is also possible that a
degree of artificial difference may be introduced through
individual register methodology and design. This exercise
also highlighted that study design has resulted in data on
other key potential confounders, such as smoking status,
being unavailable in some registers.
While this initial exercise was successful in assessing
the comparability of patient populations, data items col-
lected and data definitions, it will be challenging moving
forward to find the most effective way to combine these
data given the observed differences, considering that a
simple pooling of data will prove problematic. However,
given the need to understand the risk of rare outcomes, a
combined approach is imperative and several different
approaches will be considered, including combining only
similar registers for less rare outcomes, different statistical
methods to account for differences in patient populations
and nested casecontrol design. Work in this area is pro-
gressing and two collaborative analyses (one in melanoma
and one in lymphoma) are under way.
The purpose of this initial exercise was to understand
the availability of key data on bDMARD exposure and dif-
ferences in patient populations across Europe and how
they might influence combined analyses of rare adverse
events. It has identified variations in prescribing patterns,
recruitment strategies and data items collected.
Differences in patient populations have also been
identified in terms of disease activity and co-morbidities,
which may lead to disparity in expected adverse event
rates. While this initial analysis is an overview of the base-
line characteristics and not a long-term assessment of
safety, it is important that all registers consider collecting
information on the confounding baseline characteristics
so they can be accounted for in the future. Work is on-
going within the EULAR that aims to harmonize both data
domains as well as data collection within domains across
future RA cohort studies [19, 20]. A challenge now for in-
vestigators is to identify the most effective way to com-
bine these data given the observed differences and, on
the basis of these differences, to work towards harmon-
ization in methods of data collection across European
rheumatology.
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